Vitiligo in the affected breast during neo-adjuvant chemotherapy for breast cancer.
Rao
Maithili V
MV
James P. Wilmot Cancer Center, Department of Medicine, University of Rochester, NY, USA. maithili_rao@urmc.rochester.edu
Shayne
Michelle
M
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D014820:Vitiligo / Q000139:chemically induced*
D004317:Doxorubicin; D003520:Cyclophosphamide